Repros Therapeutics Inc (RPRX)

[WallStreet123]

"LFT ULN is a well-described safety factor"

Yes it is. Take Lipitor for example. On Lipitor's label it speaks about cases of patients being over 3x ULN. Ranges of APPROVED DOSES range from approximately <1% to 3%. In my opinion, Repros believes that efficacy is equivalent for all 3 doses so why create noise/distractions to dampen the efficacy signal by taking a dose forward that is ~4% when the other 2 doses are below 1%.
The only "beef" that anyone could have that I can see is POSSIBLY that a more rigorous look at the data could have teased this out after phase 2 data (phase 2 is done in part to chose phase 3 dose).